Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
1,045
datasets available to search
ShareScore release 0.9.0
Dataset results
1,045 results for “neoadjuvant chemotherapy”
Neoadjuvant Chemoradiotherapy and Adjuvant Chemotherapy in Treating Patients Who Are Undergoing Surgical Resection for Locally Advanced Rectal Cancer
ClinicalTrials.gov study NCT00081289. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Phase II Trial of Neoadjuvant Metronomic Chemotherapy in Triple-Negative Breast Cancer
ClinicalTrials.gov study NCT00542191. IPD Sharing: Not stated. Countries: 1. Publications: 17.
Talimogene Laherparepvec in Combination With Neoadjuvant Chemotherapy in Triple Negative Breast Cancer
ClinicalTrials.gov study NCT02779855. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Study of Pembrolizumab With or Without Defactinib Following Chemotherapy as a Neoadjuvant and Adjuvant Treatment for Resectable Pancreatic Ductal Adenocarcinoma
ClinicalTrials.gov study NCT03727880. IPD Sharing: UNDECIDED. Countries: 1. Publications: 1.
Melatonin Effect in Combination With Neoadjuvant Chemotherapy to Clinical Response in Locally Advanced Oral Squamous Cell Carcinoma
ClinicalTrials.gov study NCT04137627. IPD Sharing: NO. Countries: 1. Publications: 1.
Extracellular Fluid Changes During Neoadjuvant Chemotherapy
ClinicalTrials.gov study NCT07315880. IPD Sharing: UNDECIDED. Countries: 1. Publications: 2.
A Study of Neoadjuvant Chemotherapy Plus Nivolumab Versus Neoadjuvant Chemotherapy Plus Placebo, Followed by Surgical Removal and Adjuvant Treatment With Nivolumab or Placebo for Participants With Sur
ClinicalTrials.gov study NCT04025879. IPD Sharing: Not stated. Countries: 22. Publications: 5.
Neoadjuvant Chemotherapy for Patients With Squamous Cell Carcinoma of the Penis
ClinicalTrials.gov study NCT00512096. IPD Sharing: Not stated. Countries: 1. Publications: 1.
NEO: Neoadjuvant Chemotherapy, Excision and Observation for Early Rectal Cancer
ClinicalTrials.gov study NCT03259035. IPD Sharing: NO. Countries: 2. Publications: 1.
A Neoadjuvant Study of Nivolumab Plus Ipilimumab or Nivolumab Plus Chemotherapy Versus Chemotherapy Alone in Early Stage Non-Small Cell Lung Cancer (NSCLC)
ClinicalTrials.gov study NCT02998528. IPD Sharing: Not stated. Countries: 15. Publications: 6.
Clinical Efficacy of the Neoadjuvant Chemotherapy for IB2 and IIA2 Stage Cervical Cancer Patients
ClinicalTrials.gov study NCT03308591. IPD Sharing: UNDECIDED. Countries: 1. Publications: 1.
Neoadjuvant Chemotherapy Versus Radiochemotherapy for Cancer of the Esophagus or Cardia
ClinicalTrials.gov study NCT01362127. IPD Sharing: UNDECIDED. Countries: 1. Publications: 7.
Platinum in Treating Patients With Residual Triple-Negative Breast Cancer Following Neoadjuvant Chemotherapy
ClinicalTrials.gov study NCT02445391. IPD Sharing: YES. Countries: 2. Publications: 2.
A Study of Trastuzumab Emtansine (T-DM1) Sequentially With Anthracycline-based Chemotherapy, as Adjuvant or Neoadjuvant Therapy for Patients With Early Stage Herceptin (HER)2-positive Breast Cancer
ClinicalTrials.gov study NCT01196052. IPD Sharing: Not stated. Countries: 8. Publications: 1.
Comparison of Neoadjuvant Chemotherapy With Weekly Paclitaxel or Eribulin Followed by A/C in Women With Locally Advanced HER2-Negative Breast Cancer
ClinicalTrials.gov study NCT01705691. IPD Sharing: Not stated. Countries: 2. Publications: 1.
PET-MR for Prediction and Monitoring of Response to Neoadjuvant Chemotherapy in Breast Cancer
ClinicalTrials.gov study NCT01190566. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Data from: Neoadjuvant and concurrent chemotherapy have varied impacts on the prognosis of patients with the ascending and descending types of nasopharyngeal carcinoma treated with intensity-modulated radiotherapy
Purpose: To compare the outcomes of patients with ascending type (T4&N0-1) and descending type (T1-2&N3) of nasopharyngeal carcinoma (NPC) treated with concurrent chemoradiotherapy (CCRT), neoadjuvant chemotherapy (NACT) + intensity-modulated radiotherapy (RT) or NACT + CCRT. Methods: Retrospective analysis of 839 patients with ascending or descending types of NPC treated at a single institution between October 2009 to February 2012. CCRT was delivered to 236 patients, NACT + RT to 302 patients, and NACT + CCRT to 301 patients. Results: The 4-year overall survival rate, distant metastasis-free survival rate, local relapse-free survival rate, nodal relapse-free survival rate, loco-regional relapse-free survival rate, and progression free survival rate were 75.2% and 73.4% (P = 0.114), 85.7% and 74.1% (P = 0.008), 88.8% and 97.1% (P = 0.013), 96.9% and 94.1% (P = 0.122), 86.9% and 91.2% (P = 0.384), 73.7% and 66.2% (P = 0.063) in ascending type and descending type. Subgroup analyses indicated that NACT + RT significantly improved distant metastasis-free survival rate and progression-free survival rate when compared with CCRT in the ascending type, and there were no significant differences between the survival curves of NACT +RT and NACT + CCRT. For descending type, there were no significant differences among the survival curves of NACT +RT, CCRT, and NACT + CCRT groups, and the survival benefit mainly came from CCRT. Conclusions: Compared with NACT + CCRT or CCRT, NACT + RT may be a reasonable approach for ascending type; Although concurrent chemotherapy was effective in descending type, NACT + CCRT may be a more appropriate strategy for descending type.
NanoString dataset for study: Dynamic changes in the NK-, Neutrophil-, and B-cell immunophenotypes relevant in high metastatic risk post neoadjuvant chemotherapy–resistant early breast cancers
<p>Pre-processed DSP and mRNA abundance datasets used in this study.</p>
A multimodal and fully automated system for prediction of pathological complete response to neoadjuvant chemotherapy in breast cancer
Open the record for dataset details and reuse information.
No Axillary Surgical Treatment in Clinically Lymph Node Negative Patients on Ultrasonography After Neoadjuvant Chemotherapy
ClinicalTrials.gov study NCT06704945. IPD Sharing: YES. Countries: 1. Publications: 2.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.